Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quick start combined oral contraceptive after ellaOne or placebo
NL-OMON37370Phase 4Active, not recruiting
- Sponsor
- HRA Pharma
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in contraception comparing ellaOne followed by combined oral contraceptive with placebo followed by combined oral contraceptive (2 arms). Primary endpoints: Largest follicle diameter by transvaginal ultrasound, Endometrial thickness by transvaginal ultrasound and 2 more. Started Mar 2012; status: active, not recruiting.
02
Drugs
ulipristal
03
Conditions
contraception
Beyond the preview
Go deeper on NL-OMON37370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37370.